Key result
Ongoing trials for ultrarare GNE myopathy focus on sialic acid supplementation to address synthesis defects.
Why the study?
To review the history, clinical aspects, prior treatment trials, challenges, and unmet needs related to GNE myopathy.
This review summarizes the history, clinical aspects, and prior treatment trials for GNE myopathy, highlighting challenges and unmet needs.
Answers are grounded in this paper and cite their sources.
May guide trial enrollment in sialic acid supplementation; leaves open efficacy, safety, and practice change.
GNE myopathy is an ultrarare muscle disease characterized by slowly progressive muscle weakness. Symptoms typically start in early adulthood, with weakness and atrophy in the tibialis anterior muscles and with slow progression over time, which largely spares the quadriceps muscles. Muscle biopsy shows atrophic fibers and rimmed vacuoles without inflammation. Inherited in an autosomal recessive manner, patients with GNE myopathy carry mutations in the GNE gene which affect the sialic acid synthesis pathway. Here, we look at the history and clinical aspects of GNE myopathy, as well as focus on prior treatment trials and challenges and unmet needs related to this disorder.
No takes yet. Share an insight, caveat, or question.
Mullen et al. (2022) conducted a review in GNE myopathy. Sialic acid supplementation and other therapies was evaluated. GNE myopathy is an ultrarare autosomal recessive muscle disease caused by mutations in the GNE gene affecting sialic acid synthesis, with ongoing therapeutic trials focusing on sialic acid supplementation.
Synapse has enriched 10 related papers. Consider them for comparative context: